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The arginine stimulation test: timing of peak is 
not a helpful parameter in the diagnosis of growth 
hormone deficiency
Abstract
Background: A typical peak timing in the glucagon stimu-
lation test has been reported as an indication of growth 
hormone (GH) deficiency. Other stimulation tests have not 
been evaluated.
Objective: To evaluate the clinical usefulness of peak 
timing in the arginine stimulation test (AST) for growth 
hormone deficiency.
Methods: Retrospective review of 199 ASTs from one 
center. Outcomes included correlation of peak times with 
(a) frequency of deficient peak; (b) growth velocity stand-
ard deviation scores (GVSDSs); (c) other evidence of pitui-
tary pathology; (d) results of confirmatory clonidine test; 
and (e) response to GH treatment.
Results: The peak in 83/109 (76.14%) sufficient tests 
occurred at typical times vs. 45/72 (62.5%) deficient tests 
(p < 0.05). GVSDS on GH treatment was greater among 
patients with typical timing in the AST compared with 
atypical timing (2.67 ± 0.59 vs. 0.46 ± 1.17, p = 0.021). No other 
variable correlated significantly with AST timing.
Conclusions: Timing of peak in the AST is not a clinically 
useful parameter.
Keywords: arginine; growth hormone deficiency; short 
stature.
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Introduction
The arginine stimulation test (AST) is a commonly used 
dynamic test for the evaluation of growth hormone (GH) 
deficiency (1). In this test, blood samples are taken before 
intravenous administration of arginine and then at further 
fixed times over the next 2 h. Interpretation of this test 
relies solely on the maximum (peak) value of the samples; 
currently, in Israel, a peak above 7.5 ng/mL according to 
the current standard, or 10 ng/mL according to the old 
standard (for details, see the Methods section), is consid-
ered indicative of GH deficiency (2). In our practice, as pre-
viously reported, the most common time for occurrence of 
the peak value was at 45 min after injection (3). This was 
similar to the peak times reported in the earliest descrip-
tions of this test (4, 5). Our group reported previously that, 
for the glucagon stimulation test (GST), most patients 
had peak levels of growth hormone 90 or 120  min after 
stimulation. Those patients whose peak growth hormone 
levels occurred either unusually early after stimulation 
(i.e., before 90 min) or unusually late (i.e., more than 
120 min after the stimulus) were more likely to have other 
evidence for GH deficiency. We termed these as “atypical” 
timing compared with tests at which peak occurred 90 or 
120 min after glucagon administration which were termed 
“typical” (6). We suggested that similar studies should be 
undertaken for other growth hormone stimulation tests 
in order to evaluate the clinical usefulness of timing as 
a parameter of growth hormone secretory dynamics. We 
therefore retrospectively analyzed all ASTs performed in 
a single center and ordered by a single physician (DG) 
between October 2007 and September 2011.
Methods
AST is the first dynamic test performed at the Hadassah-Hebrew 
University Medical Center when GH deficiency is suspected. Indica-
tions for evaluation of GH status vary, but generally include height 
less than the third percentile or height standard deviation score sig-
nificantly lower than family appropriate target range, an abnormal 
growth rate and a delayed bone age. Testing for GH deficiency is 
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Table 1 GH results for each time sample for 81 deficient tests and 
118 sufficient tests.
Deficient tests, ng/mL Sufficient tests, ng/mL Sample 
time, minmean ± SE mean ± SE
1.61 ± 0.2 2.74 ± 0.4 0
3.31 ± 0.27 10.58 ± 0.9 30
3.4 ± 0.29 12.56 ± 1.0 45
3.05 ± 0.29 10.86 ± 0.9 60
2.57 ± 0.25 7.43 ± 0.7 90
2.84 ± 0.28 6.48 ± 0.7 120
undertaken after exclusion of other causes of growth retardation 
such as anemia, celiac disease, hypothyroidism, renal or liver dis-
ease, and chronic inflammation (6).
The AST procedure is performed as follows: a blood sample 
(designated 0 min) for growth hormone is taken prior to intravenous 
infusion of arginine (0.5 g/kg body weight administered over 30 min). 
The next sample is taken immediately after the infusion (designated 
the 30-min sample) and then at 45, 60, 90 and 120 min. Girls aged 
11 years and 6 months or above are primed with 2 mg of beta estradiol 
(or equivalent estrogen) orally each day for 3 days up to the day before 
the test. Boys aged above 13 years are given a single intramuscular in-
jection of 100 mg testosterone enanthate 7–10 days prior to the test. 
Currently, serum growth hormone concentration is tested using the 
Immulite 2000 analyzer chemiluminescent test ( Siemens,  Erlangen, 
Germany) with the international standard IS 98/574 (7). The current 
standard was introduced in our laboratory on July 1, 2010, and there-
fore the results of GH tested before July 2010 were normalized accord-
ing to the new figures, i.e., multiplied by 0.75.
As mentioned above, in Israel the AST is considered indicative 
of GH deficiency if the highest GH level is less than 10 ng/mL using 
the older standard or 7.5 ng/mL with the current IS 98/574 standard. 
When the AST peak is below these thresholds, a second confirmatory 
test, with clonidine as the GH stimulant, is performed. If the peak 
in the clonidine stimulation test (CST) is also below 7.5 ng/mL, GH 
deficiency is diagnosed. When there is a priori radiological evidence 
of a condition associated with GH deficiency (e.g., ectopic posterior 
pituitary or “empty sella”) or if the patient has another pituitary hor-
mone deficiency, then a single deficient stimulation test (usually the 
AST) is considered diagnostic. Results of all ASTs performed in our 
center and ordered between October 2007 and September 2010 by a 
single physician (DG) were reviewed. In total, there were 199 ASTs. 
Five patients underwent two ASTs during this time and we arbitrarily 
analyzed only the latter of the two in order to avoid intra-patient vari-
ation. For 13 tests, the peak occurred before stimulation. These were 
excluded from the current analysis since the peak time was thought 
to have reflected the fluke occurrence of a spontaneous GH peak just 
prior to the arginine stimulus. Since there is a refractory period im-
mediately after a burst of growth hormone secretion during which 
the pituitary’s response to stimuli is reduced (8), these tests could 
not be included when evaluating the timing of response to arginine. 
After the exclusions, 181/199 tests were analyzed further in order to 
evaluate the significance of the peak time.
Growth velocity was based on height measurements taken 
during clinic visits between 3 and 15  months prior to the test. 
Growth velocity standard deviation scores (GVSDSs) were calcu-
lated using the Auxology program version 1.0 (Copyright 2003 
Pfizer Pharmaceuticals) according to the UK-Tanner reference ta-
bles 2000.
Evidence for pituitary pathology was defined as presence of one 
or more of the following: at least one other pituitary hormone defi-
ciency, familial GH deficiency, an anatomic anomaly of the pituitary 
known to be associated with GH deficiency based on magnetic reso-
nance imaging or history of irradiation. These data were collected 
from electronic clinic notes of one of us (DG).
Statistics
In order to investigate the correlation between two qualitative vari-
ables, we used the chi-square test or the Fisher’s exact test. In order 
to compare two independent groups for quantitative variables, we 
used either the t-test or a parametric Mann-Whitney test. To investi-
gate changes within a group for quantitative variables, we used the 
matched t test or a parametric Wilcoxon test.
The data collected included birth date, growth data, parental 
heights, arginine test results, clonidine test results and details of past 
medical history. Results are presented as average ± standard error.
Ethics
The chart review was approved by the institutional review board of 
the Hadassah-Hebrew University Medical Center.
Results
A total of 199 arginine tests were performed, of which 
before exclusions 81 were considered deficient and 118 
were considered sufficient. Average results for each 
sample time for tests defined as deficient vs. results for 
tests defined as sufficient are presented in Table 1. After 
applying exclusion criteria (see Methods), 181 arginine 
tests were included in the analyses regarding the impor-
tance of peak times. Among these, 45 min was the most 
frequent peak time (in 31.5% of the tests) (Figure 1). A total 
of 109 (60.2%) of 181 test results indicated GH sufficiency, 
i.e., peak GH was over 7.5 ng/mL (or 10 ng/mL before July 
1, 2010) in at least one sample.
We defined early peak times as “typical” since, of the 
total five time points studied, the observed frequency of 
the peak occurring at the three earliest time points (30, 
45 and 60 min) was 70.7%, significantly greater than 
the expected 3/5 = 60% (p < 0.005). Conversely, peaks 
occurring at the two later times (i.e., 90 or 120 min) 
were defined as “atypical”. Of note, among 109 tests 
defined as “sufficient”, the average serum GH was above 
the threshold of 7.5 ng/mL at each of the three sample 
times designated as “typical” (Table 1). The average age 
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at testing among the 181 tests was 8.9 ± 3.7 years (range 
0.65–17.46). The two groups (typical vs. atypical) were 
comparable in terms of proportion of the group primed 
with sex hormones (typical: 25/128 = 19.5%, atypical: 
8/53 = 15.1%; p = 0.48).
Frequency of typical times vs. test result in 
the arginine test
The peak GH levels in tests indicating GH sufficiency 
(“sufficient tests”) occurred more often at typical times 
when compared to tests indicating GH deficiency (“defi-
cient tests”). Among the sufficient tests, 83/109 (76.14%) 
occurred at typical times. Among deficient tests, 45/72 
(62.5%) occurred at typical times (χ2 = 3.9, p < 0.05).
Consistency of typical/atypical timing upon 
repeated testing
Of the five patients tested twice, three patients were con-
sistent vis-à-vis typicality (two remained typical and one 
remained atypical upon repeat testing). Two were incon-
sistent: one turned from atypical to typical but was pre-
pubertal at the first test and pubertal at the second test 
4 years later which could perhaps explain the difference. 
The other one who turned from typical to atypical was 
tested 2 years apart, and, actually, both tests were indic-
ative of growth hormone deficiency, so that the differ-
ence may indicate a deterioration in GH secretory status 
whereby initially the child was deficient but with typical 
timing and later was deficient with atypical timing. Thus, 
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Figure 1 Histogram depicting the distribution of peak times among 
181 samples.
taken together, the repeated tests do not contradict the 
idea of peak timing as a significant factor in GH secretory 
status.
Growth velocity of patients with deficient 
ASTs
For 60 of the 72 deficient tests, GVSDS was available. 
The AST among 35 of these was typical. Average GVSDS 
was lower for the 25 children whose AST was atypical 
but did not reach statistical significance (–1.75 ± 0.45 vs. 
–0.92 ± 0.42, p = 0.19).
Growth velocity of patients with sufficient 
ASTs
The GVSDS of 88/109 patients with a sufficient AST result 
was available. The AST of 70/88 was typical. The average 
GVSDS was significantly higher for the 18 children whose 
AST was sufficient and atypical compared with sufficient 
and typical (0.2 ± 0.75 vs. –1.88 ± 0.26, p < 0.01).
Atypical timing of peak and results of  
confirmatory test
A total of 63 of 72 deficient ASTs were followed by a 
confirmatory clonidine stimulation test (CST). Of these 
ASTs, 39/63 peaked at typical timing and 24/63 were 
atypical. Seventeen (43.6%) of 39 patients with typical 
deficient ASTs were confirmed GH deficient by the CST 
and 10 (41.7%) of /24 atypical ASTs were confirmed as 
GH deficient (p = n.s.). There was therefore no significant 
correlation between typicality of timing in the AST and 
final result in terms of deficiency or sufficiency of the 
confirmatory CST.
Pituitary pathology and timing of peak
Among our cohort, 27 patients had one or more of the fol-
lowing: multiple pituitary hormone deficiency, familial 
GH deficiency, history of radiation for a brain tumor, and 
anatomic anomaly of the pituitary based on magnetic 
resonance imaging. Such evidence of significant pituitary 
pathology was noted nominally more frequently among 
patients with atypical ASTs (11/53, 20.8%) compared with 
typical ASTs (16/128, 12.5%) (p = 0.24, Fisher’s exact test, 
two tailed).
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Growth velocity on growth hormone 
treatment
We compared the growth velocity of patients who were 
treated with growth hormone for at least 6 months. Among 
16/22 treated patients with available data, the peak time 
of the AST was typical. Average GVSDS was significantly 
higher for those patients compared with the 6/22 patients 
who, prior to therapy, had atypical ASTs (2.67 ± 0.59 vs. 
0.46 ± 1.17, p = 0.021).
Discussion
Currently, the sole parameter considered by clinicians 
interpreting the AST is the peak GH level at whatever time 
it occurs. The aim of this study was to evaluate whether, 
as for the GST (6), the time at which the peak occurs could 
be another useful parameter. The results of the present 
study did not define a clinically useful role for timing of 
the peak in the diagnosis of growth hormone deficiency 
by the AST. In order to reach this conclusion, the first 
step in our analysis was to characterize typical timing. We 
defined this based on those times that occurred more fre-
quently than expected. Furthermore, in the current study, 
for ASTs considered sufficient, the average serum growth 
hormone was above the standard 7.5 ng/mL threshold 
at, and only at, each of the three times that were deter-
mined typical. These times are, in our opinion, valid for 
the above reasons and also because they are in agreement 
with the typical peak times determined in several previ-
ous studies (3–5).
The findings of the present study regarding the lack 
of utility of the peak time as a useful parameter contrast 
with those of our previous study of the GST (6). In that 
study, among those whose peak GH level was indicative 
of GH deficiency, atypical timing of the peak increased 
the chance that deficient secretion would be confirmed in 
a clonidine stimulation test (6). The other major finding 
in that study was that patients with deficient atypi-
cal GST results and sufficient confirmatory tests had a 
lower GVSDS than patients with deficient typical results 
and sufficient confirmatory tests, although data regard-
ing this issue were available only for a small number of 
patients. There was also an excellent correlation between 
“typicality” of the timing in deficient GSTs and typical-
ity of timing in the confirmatory clonidine test (6). The 
reasons for the different findings in the present study 
are unclear. Indeed, the total percentage of typical ASTs 
(70.7%) in the current study was similar to the percent 
of typical GSTs (76%) and the highest average level of 
12.56 ± 1.0 ng/mL for the AST (at 45 min) was similar to 
the 11.2 ± 0.5 ng/mL for the GST (at 120 min) (6). Also, 
physiologically, disordered patterns of secretion have 
been described as part of the growth hormone deficiency 
syndrome (9, 10). Therefore, we expected to find that 
timing in the AST would be of similar importance and 
potential usefulness. Indeed, the peak in ASTs indicat-
ing GH sufficiency tended to occur more often at typical 
times (30, 45 and 60 min) compared with the peak in tests 
indicating insufficiency. This can be interpreted to mean 
that children who, in response to arginine, secrete GH 
in adequate quantity tend to do so also rapidly, which 
would indicate physiological importance to timing. Also, 
children with evidence of pituitary pathology other than 
stimulation test results have a nominally higher chance 
of atypical timing in the AST, similar to the statistically 
significant trend for the GST. However, the results for 
correlation between timing of the peak and growth rates 
were dependent on the level of the peak. Among children 
whose AST peak was high, i.e., indicative of sufficiency, 
typical timing was associated with lower growth velo-
city. Contrarily, among those whose AST peak was low, 
i.e., indicative of deficiency, typical timing was not asso-
ciated with higher growth velocity and, in fact, typical 
timing was nominally associated with lower velocity, 
although data regarding this issue were available only for 
a relatively small subgroup of patients. We do not have 
a reasonable explanation for this finding, but whatever 
its cause, it means that peak timing is not an independ-
ent parameter since the effect of timing on growth varies 
depending on peak level. Lastly, the growth response was 
contrary to what would have been intuitively expected – 
there was a significantly decreased growth response to 
treatment among patients whose arginine peaks occurred 
at atypical times. This may reflect a concomitant inability 
to secrete factors downstream to GH among some of these 
children whose GH secretion is deficient, which could 
occur, for example, if there was a general disorder of exo-
cystosis (11). More likely, however, this simply reflects the 
known limited correlation between GH stimulation test 
results and response to therapy (12).
Overall, we conclude that, although atypical peak GH 
responses may indeed be a physiological indication of 
poor GH secretion, the effect does not appear to be poten-
tially useful in the clinical definition of GH deficiency by 
the AST.
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